Back to mobile site

Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)

September 24, 2024 5:28 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $1,292.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login